Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Gains from Investment Securities: 2014-2024

Historic Gains from Investment Securities for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Dec 2024 value amounting to $11.7 million.

  • Syndax Pharmaceuticals' Gains from Investment Securities rose 9.39% to $11.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $11.7 million, marking a year-over-year increase of 9.39%. This contributed to the annual value of $11.7 million for FY2024, which is 9.39% up from last year.
  • Latest data reveals that Syndax Pharmaceuticals reported Gains from Investment Securities of $11.7 million as of FY2024, which was up 9.39% from $10.7 million recorded in FY2023.
  • Syndax Pharmaceuticals' Gains from Investment Securities' 5-year high stood at $11.7 million during FY2024, with a 5-year trough of $6.4 million in FY2020.
  • For the 3-year period, Syndax Pharmaceuticals' Gains from Investment Securities averaged around $10.1 million, with its median value being $10.7 million (2023).
  • Data for Syndax Pharmaceuticals' Gains from Investment Securities shows a peak YoY surged of 33.87% (in 2023) over the last 5 years.
  • Syndax Pharmaceuticals' Gains from Investment Securities (Yearly) stood at $6.4 million in 2020, then increased by 8.50% to $6.9 million in 2021, then climbed by 15.32% to $8.0 million in 2022, then soared by 33.87% to $10.7 million in 2023, then climbed by 9.39% to $11.7 million in 2024.